摘要
目的:比较可切除胃癌患者术后分别采用奥沙利铂联合5-氟尿嘧啶/亚叶酸钙(FOLFOX6)与奥沙利铂联合卡培他滨(XELOX)两种方案辅助化疗的生存差异。方法:147例Ⅰ~Ⅲ期胃癌术后(R0切除)患者接受治疗,其中FOLFOX6组99例, XELOX组48例,比较两组不良反应率和生存率。结果:FOLFOX6组白细胞减少及肝功能异常的发生率明显高于XELOX组(P〈0.05),XELOX组手足综合征(HFS)的发生明显高于FOLFOX6组(P=0.016),其它不良反应的比较,包括贫血、血小板减少、恶心呕吐、腹泻、肾功能异常、外周神经毒性、口腔黏膜炎等差异无统计学意义(P〉0.05)。FOLFOX6组与XELOX组1、3、5年无病生存率(DFS)分别为81.7%、49.5%、39.8%和93.8%、52.1%、33.8%,两组中位无病生存时间(mDFS)分别为35、38个月,差异无统计学意义(P=0.672);FOLFOX6组与XELOX组1、3、5年总生存率(OS)分别为98.0%、68.1%、44.6%和97.8%、78.7%、44.7%,两组中位总生存时间(mOS)分别为55、58个月,比较亦无显著性差异(P=0.194)。结论:两种化疗方案对胃癌患者远期生存的影响无显著性差异。
Objective:To compare the survival of resected gastric cancer patient treated with oxaliplatin, 5-fluorouracil, and leu-covorin (FOLFOX6) with those treated with oxaliplatin and capecitabine (XELOX). Methods:A total of 147 resected gastric cancer pa-tients accepted the treatment. Among them, 99 were treated with FOLFOX6 and 48 were treated with XELOX. Adverse events and sur-vival rates of the two groups were compared. Results:Incidence of leukopenia and hepatic dysfunction in the FOLFOX6 group was sig-nificantly higher than that of the XELOX group (P〈0.05), whereas hand-foot syndrome in the XELOX group was significantly higher than that of the FOLFOX6 group (P=0.016). By contrast, the incidence of other adverse events, such as anemia, thrombocytopenia, nau-sea and vomiting, diarrhea, kidney dysfunction, peripheral neurovirulence, and oral mucositis, was not significantly different (P〉0.05) between the two groups. After 1, 3, and 5 years, disease-free and overall survivals between the two groups were not significantly differ-ent (P〉0.05). Conclusion:The effects of FOLFOX6 and XELOX adjuvant chemotherapies on long-term survival of resected gastric cancer patients were found to have no significant difference.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2014年第18期1195-1198,共4页
Chinese Journal of Clinical Oncology
关键词
胃癌
辅助化疗
奥沙利铂
5-氟尿嘧啶
卡培他滨
生存率
gastric cancer
adjuvant chemotherapy
oxaliplatin
5-fluorouracil
capecitabine
survival